Andy Sandham has 28 years of experience in the healthcare sector with roles covering corporate strategy, operational management, business development and marketing. He has contributed significantly to the establishment of successful drug discovery and development companies both in Europe and the US. Before joining Abingworth, Andy was Chief Executive Officer and Co-founder of Ionix Pharmaceuticals, which was divested to Vernalis plc in 2005. Prior to Ionix, he served as Chief Operating Officer of Signature BioScience, Hexagen and Cantab Pharmaceuticals. Andy has also held business development and marketing positions at Amersham, Celltech and Roche. He is currently non-executive Chairman of NeurAxon and Novacta Biosystems. He has a BSc in Chemistry from University of East Anglia and a Diploma in Marketing from the Institute of Marketing.